Showing 3691-3700 of 4066 results for "".
- Prescriber’s Choice Launches “PC Direct” and “PC Delivers”https://practicaldermatology.com/news/prescribers-choice-launches-pc-direct-and-pc-delivers/2460362/Two new options from Prescriber’s Choice enable physicians to prescribe and ship medicines directly to patients for the treatment of dozens of dermatologic conditions. The ability to ship Prescriber’s Choice medicines to patients is an alternative to existing in-office dispensing to s
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- Navigating the Ins and Outs of Your Insurance Coverage During COVID-19https://practicaldermatology.com/news/navigating-the-ins-and-outs-of-your-insurance-coverage-during-covid-19-1/2460349/Jason O’Dell, a financial consultant and insurance specialist at OJM Group, spoke with New Jersey-based dermatologist Jeanine Downie, MD and Chicagoland facial plastic surgeon Steve Dayan, MD about what to expect from insurance coverage during the pandemic and how to beef up your policies i
- Novartis Terminates Sale of Sandoz US Generic Oral Solids, Dermatology Portfolio to Aurobindo in Mutual Agreementhttps://practicaldermatology.com/news/novartis-terminates-sale-of-sandoz-us-generic-oral-solids-dermatology-portfolio-to-aurobindo-in-mutual-agreement/2460332/In a mutual agreement with Aurobindo Pharma USA Inc., Novartis has terminated the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo. This decision was taken as approval from the U.S. Federal Trade Commission for the transaction was not obtained within ant
- FDA Accepts NDA for Almirall's AK Drug Tirbanibulinhttps://practicaldermatology.com/news/fda-accepts-nda-for-almiralls-ak-drug-tirbanibulin/2460299/The FDA has reviewed and accepted the New Drug Application (NDA) from Almirall, SA for tirbanibulin, also known as ALM14789, for the treatment of actinic keratosis (AK). The FDA also communicated that it is not currently planning on holding an advisory committee to discuss the application. <
- Sun Pharma Survey: Impact of Psoriasis on Patients is Extensivehttps://practicaldermatology.com/news/sun-pharma-survey-impact-of-psoriasis-on-patients-is-extensive/2460284/The impact of moderate-to-severe plaque psoriasis on social and personal interactions can be extensive, results of a new survey from Sun Pharma confirm. In fact, 44 percent of respondents said that they often or sometimes feel humiliated by the appearance of psoriasis. More than a quarter (28 per
- Allergan Launches New Philanthropic Program Benefitting Kids with Upper Limb Spasticityhttps://practicaldermatology.com/news/allergan-launches-new-philanthropic-program-benefitting-kids-with-upper-limb-spasticity/2460274/Allergan is launching the Be The Difference philanthropic program to support children and their families who may benefit from treatment with Botox (onabotulinumtoxinA) for pediatric upper limb spasticity. Botox is approved to treat increased muscle stiffness in children 2 to 17 years of
- Neuromodulators and Fillers Top RealSelf's List of Most Worth It Procedures of 2020https://practicaldermatology.com/news/neuromodulators-and-fillers-top-realselfs-list-of-most-worth-it-procedures-of-2020-1/2460272/A total of 15 nonsurgical and 37 surgical procedures earned Real Self’s Most Worth It designation for 2020. The RealSelf Worth It Rating is a proprietary consumer satisfaction score based on reviews from consumers on RealSelf who, after undergoing a treatment, rated it as "Wo
- Final Data Support Efficacy of Revian Red System for Hair Growthhttps://practicaldermatology.com/news/final-data-support-efficacy-of-revian-red-system-for-hair-growth/2460260/Final data from a randomized, double-blind study of the Revian Red hair growth system demonstrated the ability of the system to successfully stop hair loss and subsequently grow new hair. Findings were presented at the 2020 Winter Clinical Dermatology Conference – Hawaii and are <
- Revian Awarded Patent for Biostimulatory Light Combinationshttps://practicaldermatology.com/news/revian-awarded-patent-for-biostimulatory-light-technology/2460249/Revian Inc. has received from the United States Patent and Trademark Office (USPTO) U.S. Patent No. 10,265,258—the seminal patent on the use of proprietary color combinations of light to regenerate living tissue in the body. The claims in this issued patent cover the u